{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:57:09Z","timestamp":1792421829943,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejmech.2021.114092","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T11:22:18Z","timestamp":1640863338000},"page":"114092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia"],"prefix":"10.1016","volume":"229","author":[{"given":"Zean","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peihua","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goverdhan","family":"Surineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingzheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5668-6572","authenticated-orcid":false,"given":"Jianjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.114092_bib1","first-page":"177","article-title":"Hyperuricemia and gout","volume":"15","author":"Sorensen","year":"1969","journal-title":"Adv. Intern. Med."},{"key":"10.1016\/j.ejmech.2021.114092_bib2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.rdc.2006.02.005","article-title":"Hyperuricemia and associated diseases","volume":"32","author":"Becker","year":"2006","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"10.1016\/j.ejmech.2021.114092_bib3","series-title":"Gout","author":"Dalbeth","year":"2021"},{"key":"10.1016\/j.ejmech.2021.114092_bib4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/VHRM.S4265","article-title":"Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress","volume":"5","author":"George","year":"2009","journal-title":"Vasc. Health Risk Manag."},{"key":"10.1016\/j.ejmech.2021.114092_bib5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/0305-0491(85)90381-5","article-title":"On the loss of uricolytic activity during primate evolution-I. Silencing of urate oxidase in a hominoid ancestor","volume":"81","author":"Friedman","year":"1985","journal-title":"Comp. Biochem. Physiol. B"},{"key":"10.1016\/j.ejmech.2021.114092_bib6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11926-012-0240-z","article-title":"Regulation of uric acid excretion by the kidney","volume":"14","author":"Lipkowitz","year":"2012","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.ejmech.2021.114092_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030456","article-title":"Extra-renal elimination of uric acid via intestinal efflux transporter BCRP\/ABCG2","volume":"7","author":"Hosomi","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2021.114092_bib8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/BOR.0000000000000573","article-title":"The role of febuxostat in gout","volume":"31","author":"Bardin","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.ejmech.2021.114092_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0002-9343(84)90743-5","article-title":"Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency","volume":"76","author":"Hande","year":"1984","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejmech.2021.114092_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jbspin.2016.04.007","article-title":"Patients with gout differ from healthy subjects in renal response to changes in serum uric acid","volume":"84","author":"Liu","year":"2017","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ejmech.2021.114092_bib11","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.2174\/138161205774913219","article-title":"Uric acid and the kidney: urate transport, stone disease and progressive renal failure","volume":"11","author":"Capasso","year":"2005","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2021.114092_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-biophys-060414-033901","article-title":"Structural biology of the major facilitator superfamily transporters","volume":"44","author":"Yan","year":"2015","journal-title":"Annu. Rev. Biophys."},{"key":"10.1016\/j.ejmech.2021.114092_bib13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrm.2015.25","article-title":"Understanding transport by the major facilitator superfamily (MFS): structures pave the way","volume":"17","author":"Quistgaard","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2021.114092_bib14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1152\/physrev.00025.2013","article-title":"The organic anion transporter (OAT) family: a systems biology perspective","volume":"95","author":"Nigam","year":"2015","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2021.114092_bib15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000074539","article-title":"Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux","volume":"13","author":"Bakhiya","year":"2003","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejmech.2021.114092_bib16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s12565-016-0369-3","article-title":"Roles of organic anion transporters (OATs) in renal proximal tubules and their localization","volume":"92","author":"Otani","year":"2017","journal-title":"Anat. Sci. Int."},{"key":"10.1016\/j.ejmech.2021.114092_bib17","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1038\/s41467-020-16525-w","article-title":"The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion","volume":"11","author":"Hoque","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2021.114092_bib18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.ASN.0000105320.04395.D0","article-title":"Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion","volume":"15","author":"Ichida","year":"2004","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.ejmech.2021.114092_bib19","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/ng.106","article-title":"SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout","volume":"40","author":"Vitart","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ejmech.2021.114092_bib20","doi-asserted-by":"crossref","first-page":"R220","DOI":"10.1186\/ar4417","article-title":"Association analysis of the SLC22A11 (organic anion transporter 4) and SLC22A12 (urate transporter 1) urate transporter locus with gout in New Zealand case-control sample sets reveals multiple ancestral-specific effects","volume":"15","author":"Flynn","year":"2013","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ejmech.2021.114092_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/BOR.0000000000000476","article-title":"New urate-lowing therapies","volume":"30","author":"Abhishek","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.ejmech.2021.114092_bib22","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1177\/1060028018762103","article-title":"Lesinurad: a novel agent for management of chronic gout","volume":"52","author":"Haber","year":"2018","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2021.114092_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10157-019-01811-9","article-title":"Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia","volume":"24","author":"Kuriyama","year":"2020","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.ejmech.2021.114092_bib24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/jpet.119.259341","article-title":"Pharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor","volume":"371","author":"Taniguchi","year":"2019","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2021.114092_bib25","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41598-017-00706-7","article-title":"Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout","volume":"7","author":"Tan","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.114092_bib26","doi-asserted-by":"crossref","first-page":"26834","DOI":"10.1074\/jbc.C800156200","article-title":"Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans","volume":"283","author":"Anzai","year":"2008","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.114092_bib27","doi-asserted-by":"crossref","first-page":"F612","DOI":"10.1152\/ajprenal.00139.2009","article-title":"Mouse GLUT9: evidences for a urate uniporter","volume":"297","author":"Bibert","year":"2009","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejmech.2021.114092_bib28","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.ajhg.2008.11.001","article-title":"Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia","volume":"83","author":"Matsuo","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ejmech.2021.114092_bib29","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1080\/15257770.2011.623685","article-title":"Pathogenic GLUT9 mutations causing renal hypouricemia type 2 (RHUC2)","volume":"30","author":"Kawamura","year":"2011","journal-title":"Nucleos Nucleot. Nucleic Acids"},{"key":"10.1016\/j.ejmech.2021.114092_bib30","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10157-015-1186-z","article-title":"Functional analysis of novel allelic variants in URAT1 and GLUT9 causing renal hypouricemia type 1 and 2","volume":"20","author":"Mancikova","year":"2016","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.ejmech.2021.114092_bib31","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ki.2010.206","article-title":"A\u00a0'complexity' of urate transporters","volume":"78","author":"Wright","year":"2010","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejmech.2021.114092_bib32","doi-asserted-by":"crossref","first-page":"15501","DOI":"10.1073\/pnas.0904411106","article-title":"Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy","volume":"106","author":"Preitner","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2021.114092_bib33","article-title":"CDER167, a dual inhibitor of URAT1 and GLUT9, is a novel and potent uricosuric candidate for the treatment of hyperuricemia","author":"Zhao","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2021.114092_bib34","doi-asserted-by":"crossref","first-page":"33421","DOI":"10.1021\/acsomega.0c05360","article-title":"Structural insights into the atomistic mechanisms of uric acid recognition and translocation of human urate anion transporter 1","volume":"5","author":"Zhao","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2021.114092_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/srep34995","article-title":"Mechanism of high affinity inhibition of the human urate transporter URAT1","volume":"6","author":"Tan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.114092_bib36","doi-asserted-by":"crossref","first-page":"F527","DOI":"10.1152\/ajprenal.00134.2012","article-title":"Human SLC2A9a and SLC2A9b isoforms mediate electrogenic transport of urate with different characteristics in the presence of hexoses","volume":"303","author":"Witkowska","year":"2012","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.ejmech.2021.114092_bib37","doi-asserted-by":"crossref","first-page":"E831","DOI":"10.1152\/ajpendo.00296.2009","article-title":"Facilitative glucose transporter 9, a unique hexose and urate transporter","volume":"297","author":"Doblado","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2021.114092_bib38","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1371\/journal.pmed.0050197","article-title":"SLC2A9 is a high-capacity urate transporter in humans","volume":"5","author":"Caulfield","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.ejmech.2021.114092_bib39","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1152\/physiolgenomics.00207.2007","article-title":"Multiple organic anion transporters contribute to net renal excretion of uric acid","volume":"33","author":"Eraly","year":"2008","journal-title":"Physiol. Genom."},{"key":"10.1016\/j.ejmech.2021.114092_bib40","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1038\/srep03755","article-title":"ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload","volume":"4","author":"Matsuo","year":"2014","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.114092_bib41","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3389\/fphar.2016.00518","article-title":"Identification of febuxostat as a new strong ABCG2 inhibitor: potential applications and risks in clinical situations","volume":"7","author":"Miyata","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.114092_bib42","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1146\/annurev-pharmtox-010617-052713","article-title":"The SLC22 transporter family: a paradigm for the impact of drug transporters on metabolic pathways, signaling, and disease","volume":"58","author":"Nigam","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2021.114092_bib43","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nature22345","article-title":"Structure of the human multidrug transporter ABCG2","volume":"546","author":"Taylor","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2021.114092_bib44","first-page":"2018","article-title":"Analysis of cell viability by the MTT assay","author":"Kumar","year":"2018","journal-title":"Cold Spring Harb. Protoc."},{"key":"10.1016\/j.ejmech.2021.114092_bib45","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/978-1-59745-526-8_22","article-title":"Recording hERG potassium currents and assessing the effects of compounds using the whole-cell patch-clamp technique","volume":"491","author":"Helliwell","year":"2008","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejmech.2021.114092_bib46","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1254\/jphs.08102FP","article-title":"Molecular determinants of hERG channel block by terfenadine and cisapride","volume":"108","author":"Kamiya","year":"2008","journal-title":"J.\u00a0Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2021.114092_bib47","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.str.2007.06.004","article-title":"Conformational change in an MFS protein: MD simulations of LacY","volume":"15","author":"Holyoake","year":"2007","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2021.114092_bib48","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1021\/acs.jcim.9b00494","article-title":"Discovery of novel Pim-1 kinase inhibitors with a flexible-receptor docking protocol","volume":"59","author":"Li","year":"2019","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2021.114092_bib49","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1177\/2472555220949501","article-title":"Characterizations of the urate transporter, GLUT9, and its potent inhibitors by patch-clamp technique","volume":"26","author":"Chen","year":"2021","journal-title":"SLAS Discov."},{"key":"10.1016\/j.ejmech.2021.114092_bib50","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.dmpk.2017.11.002","article-title":"Investigation of the transport of xanthine dehydrogenase inhibitors by the urate transporter ABCG2","volume":"33","author":"Nakamura","year":"2018","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2021.114092_bib51","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1007\/s11095-006-9181-4","article-title":"Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles","volume":"24","author":"Rizwan","year":"2007","journal-title":"Pharm. Res. (N. Y.)"},{"key":"10.1016\/j.ejmech.2021.114092_bib52","doi-asserted-by":"crossref","first-page":"10829","DOI":"10.1021\/acs.jmedchem.0c00223","article-title":"Novel human urate transporter 1 inhibitors as hypouricemic drug candidates with favorable druggability","volume":"63","author":"Zhao","year":"2020","journal-title":"J.\u00a0Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421009417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421009417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:39:23Z","timestamp":1759329563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421009417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":52,"alternative-id":["S0223523421009417"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114092","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of novel verinurad analogs as dual inhibitors of URAT1 and GLUT9 with improved Druggability for the treatment of hyperuricemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114092","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114092"}}